

1 **Impact of COVID-19 on diabetes mellitus outcomes and care in sub-Saharan Africa:**

2 **A scoping review.**

3 Wenceslaus Sseguya^{1,4*}, Silver Bahendeka^{3,4}, Sara MacLennan¹, Nimesh Mody² & Aravinda

4 Meera Guntupalli¹,

5 ¹ Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom

6 ² Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom

7 ³ Mother Kevin Postgraduate Medical School, Uganda Martyrs University, Kampala, Uganda

8 ⁴ Department of Internal Medicine, St Francis Hospital Nsambya, Kampala, Uganda

9 *Corresponding author

10 Email: w.sseguya.21@abdn.ac.uk (WS)

11 **Abstract**

12 Background

13 The COVID-19 pandemic impacted diabetes mellitus clinical outcomes and chronic care
14 globally. However, little is known about its impact in low-resource settings such as sub-Saharan
15 Africa. Hence, to address this, we systematically conducted a scoping review to explore the
16 COVID-19 impact on diabetes outcomes and care in countries of sub-Saharan Africa.

17 Methods

18 We applied our search strategy to PubMed, Web of Science, CINAHL, African Index Medicus,
19 Google Scholar, Cochrane Library, Scopus, Science Direct, ERIC and Embase to obtain relevant
20 articles published from January 2020 to March 2023. Two independent reviewers were involved
21 in the screening of retrieved articles. Data from eligible articles were extracted from
22 quantitative, qualitative and mixed methods studies. Numerical data were summarised using
23 descriptive statistics, while a thematic framework was used to categorise and identify themes
24 for qualitative data.

25 Results

26 We found 42 of the retrieved 360 articles eligible, mainly from South Africa, Ethiopia and
27 Ghana (73.4%). COVID-19 increased the risk of death (OR 1.30 – 9.0, 95% CI), hospitalisation
28 (OR 3.30 – 3.73; 95% CI), and severity (OR: 1.30-4.05, 95% CI) in persons with diabetes
29 mellitus. COVID-19 also increased the risk of developing diabetes mellitus in hospitalised cases.
30 The pandemic, on the other hand, was associated with disruptions in patient self-management
31 routine and diabetes mellitus care service delivery. Three major themes emerged, namely, (i)
32 patient-related health management challenges, (ii) diabetes mellitus care service delivery
33 challenges, and (iii) reorganisation of diabetes mellitus care delivery.

34 Conclusion

35 COVID-19 increased mortality and morbidity among people living with diabetes mellitus. In
36 addition, the COVID-19 pandemic worsened diabetes mellitus care management. Sub-Saharan
37 African countries should, therefore, institute appropriate policy considerations for persons with
38 diabetes mellitus during widespread emergencies.

39 **Introduction**

40 Global evidence suggests that the coronavirus disease 2019 (COVID-19) resulted in a
41 worldwide surge in mortality, morbidity, and disability, which predominantly occurred among
42 older adults and individuals with chronic disease conditions [1,2]. COVID-19 has been reported
43 to worsen diabetes mellitus (DM) clinical outcomes in particular, and DM care in general
44 generally [3–8]. However, very little in this context is known in low- and middle-income
45 countries, particularly in sub-Saharan Africa (SSA).

46 While SSA is estimated to be host to 24 million of the estimated 537 million people with DM
47 globally, the region records the highest rate of DM-related premature mortality [9].
48 Furthermore, SSA is predicted to experience the highest rate of rise in DM prevalence than any
49 other region by 2040, depicting the magnitude of a growing threat [9]. DM is an under-
50 researched area in SSA, which may underlie the limited understanding of the scale of the
51 COVID-19 impact on persons living with DM (PLWD) and related vulnerabilities within the
52 region. To address this gap, we carried out a scoping review to assimilate knowledge in this
53 area that supports evidence-based policy consideration and stimulates future research in this
54 field in SSA.

55 We, therefore systematically conducted a scoping review of published qualitative, quantitative
56 and mixed methods literature to explore the COVID-19 impact on DM outcomes and care in
57 SSA. Our scoping review aimed to: (i) identify and characterise impact of COVID-19 infection
58 on clinical outcomes of DM; (ii) describe DM care aspects that were impacted by the COVID-19
59 pandemic; and (iii) identify existing gaps in knowledge and research.

60 **Methods**

61 **Study design**

62 We report our scoping review in line with the Preferred Reporting Items for Systematic Reviews
63 and Meta-analyses extension for Scoping Reviews (PRISMA-ScR) (S1 PRISMA-ScR Checklist).
64 The initial protocol for this scoping review is repositd with Open Science Framework
65 [<https://doi.org/10.17605/OSF.IO/9JCKF>].

66 **Data sources and search strategy**

67 We searched ten electronic databases, i.e., PubMed, Web of Science, Cumulative Index to
68 Nursing and Allied Health Literature (CINAHL), African Index Medicus, Google Scholar,
69 Cochrane Library, Scopus, Science Direct, Education Resource Information Centre (ERIC) and
70 Embase. We defined our search strategy guided by the SPIDER (Sample population,
71 Phenomenon of Interest, Design, Evaluation and Research type) framework as outlined by
72 Cooke et al. [10] to identify relevant literature from qualitative and mixed methods studies.
73 Additionally, to capture relevant literature from quantitative studies, we enriched our search
74 strategy by incorporating appropriate elements of the PICO (Population, Intervention,
75 Comparison and Outcome) framework [11]. The detailed search strategy applied to all citation
76 databases with their respective search strings is provided as supplementary material (S2
77 Search strategy). A search across all databases was initially conducted in May 2022 and later
78 updated using the same search strategy in March 2023 to include any relevant records
79 published between the two periods. This also opened up possibilities for including studies with
80 data on various 'waves' of COVID-19 infection and emerging interventions as the pandemic
81 progressed. All retrieved records were merged into a single MS[®] Excel file for subsequent
82 removal of duplicate records and screening.

83 **Selection criteria**

84 The retrieved records were screened for eligibility through two stages, i.e., an initial review of
85 article title and abstract and a subsequent full-text review of articles to be considered in final
86 inclusion. An initial screening for the title and abstract was independently conducted by WS

87 and AMG and reviewed by SB, who also resolved any disagreements in screening decisions.
88 The same approach was applied for full-text screening. We defined agreement as a matching
89 decision independently held by the reviewers involved in the screening process.

90 The inclusion criteria were (i) articles from any country listed under SSA by the World Bank in
91 2021 [12], (ii) articles focusing on or concerning DM and COVID-19, (ii) peer-reviewed articles
92 and reports and (iv) published from 01 January 2020 – 22 March 2023. The exclusion criteria
93 were (i) no full-text availability, (ii) articles not published in the English language, (iii) non-
94 human studies, (iv) reviews, (v) articles with irrelevant scope, (vi) duplicate articles, and (vii)
95 articles published as multicountry studies involving countries outside SSA but without
96 disaggregation of country-specific data (Fig 1).

97 **Data extraction and management**

98 Data variables of interest from the selected articles were extracted and charted in the
99 extraction form. The data extraction form was developed by WS and reviewed by AMG, SB, and
100 SM. It was then tested with two randomly selected articles from each set of quantitative,
101 qualitative, and mixed methods studies for appropriateness. Appropriate revisions were made
102 and continuously refined and updated throughout the data extraction process. Data extraction
103 and charting were conducted by WS and independently reviewed by AMG and SB during the
104 extraction and charting phase.

105 **Data synthesis**

106 We used an inductive thematic approach to synthesise and collate findings of qualitative and
107 mixed-methods studies and open-ended results of quantitative studies.

108 We used SPSS[®] version 27.0 (IBM Corp, Armonk: New York) to summarise findings from
109 quantitative studies as mean (SD), range (minimum and maximum), proportions and
110 frequencies, where appropriate. Due to the variability in methodological designs of
111 interventions and outcome measures across studies, a meta-analysis was not performed.

112 **Results**

113 **Selection and characteristics of included studies**

114 A total of 360 unique records were retrieved from database searches, 42 of which were eligible
115 for final inclusion (Fig 1). Inter-reviewer reliability analysis using the Cohen's kappa showed
116 substantial agreement between reviewers at title and abstract screening ($k=0.626$, $p<0.01$),
117 and moderate agreement at full-text screening ($k=0.545$, $p<0.01$). The detailed description of
118 information of the included studies is shown in Table 1.

119 The included studies were all observational but dominated by cross-sectional design (69%),
120 with sample sizes ranging from 18 [13] to 3,460,932 [14]. The studies were predominantly
121 retrospective (66.7%) and published between 2021 and 2022 (85.7%). The majority originated
122 in South Africa (40.5%) and were mainly hospital-based (83.3%) and employed quantitative
123 methods (90.4%). The extracted data variables were, DM prevalence among COVID-19 cases,
124 outcomes of DM related to COVID-19 and their predictors, patient-related health management
125 aspects, DM care service delivery aspects, and organisation of DM care related to the
126 pandemic.

127

128

129

130 Table 1: extraction of data from included studies.

Study	Study design	Location and period (study timeline)	Sample	Phenomenon studied/intervention	Evaluation / outcome	Key findings
Mash RJ, et al. [15]	Observational cross-sectional study	rural & urban district hospitals, South Africa March 2020 - June 2020 (Retrospective)	1,376 patients admitted with COVID-19	<ul style="list-style-type: none"> ▪ Prevalence of comorbidities ▪ Predictors of mortality and length of hospitalisation 	<ul style="list-style-type: none"> ▪ Proportion ▪ Odds ratio 	<ul style="list-style-type: none"> ▪ 1. 25.2% had diabetes (20.3% among rural) ▪ Type 2 diabetes (AOR 1.84, 1.24 - 2.73, 95%CI) was independently associated with a higher risk of death. ▪ 73.2% (n=272) had uncontrolled diabetes (HbA1c>8%), 78.6% from rural hospitals
Dave JA, et al. [16]	Observational cohort	rural & urban district hospitals, western Cape, South Africa March 2020 - July 2020 (Retrospective)	9,305 persons with diabetes diagnosed with COVID-19	<ul style="list-style-type: none"> ▪ Prevalence of new-onset diabetes ▪ Predictors of hospitalization and death 	<ul style="list-style-type: none"> ▪ Proportion ▪ Odds ratio 	<ul style="list-style-type: none"> ▪ 11.3% of the diabetes cases were newly diagnosed during the COVID-19 episode. ▪ Diabetes had a high risk for COVID-19 hospital admission (OR:3.73, 95%CI 3.53,3.94) and mortality (OR:3.01,95%CI: 2.76,3.28) ▪ Insulin use was associated with increased risk for hospitalisation (OR:1.39, 95% CI:1.24,1.57) and mortality (OR:1.49, 95% CI:1.27,1.74) ▪ Metformin was associated with reduced risk for hospitalisation (OR 0.662, 95% CI:0.55,0.71) and mortality (OR 0.77, 95% CI:0.64;0.92) ▪ Being male increased risk of COVID-

						19 hospitalisation (OR 1.41, 95%CI: 1.29,1.54) and mortality (OR 1.70, 95%CI: 1.51, 1.92)
						<ul style="list-style-type: none"> Age per 5-year interval was associated with increased risk of COVID-19 hospitalisation (OR 1.15, 95%CI: 1.13,1.17) and mortality (OR 1.33, 95%CI: 1.30,1.37)
Van Hoving DJ, et al. [17]	Observational Cohort	Rural and urban hospitals in South Africa	261 hospitalised patients admitted for COVID-19 investigation	<ul style="list-style-type: none"> Prevalence of comorbidities Proportion of deaths among persons with diabetes 	<ul style="list-style-type: none"> Proportion 	<ul style="list-style-type: none"> Diabetes (19.2%) was among the common comorbidities in the admitted patients. 37.5% of deaths occurred in persons with diabetes
Ratshikho pha E. et al. [18]	Observational cross-sectional study	Urban hospitals, South Africa	10,149 health workers	<ul style="list-style-type: none"> Prevalence of comorbidities Predictors of COVID-19 severity 	<ul style="list-style-type: none"> Proportion Odds ratio 	<ul style="list-style-type: none"> 27.6% of COVID-19 cases had diabetes. comorbid diabetes (aOR: 1.3, 95%CI 1.2-1.5) was associated with a higher risk for disease severity.
Claassen N, et al. [19]	Observational cross-sectional study	Urban hospital in Cape Town, South Africa	568 admitted patients with confirmed SARS-CoV2	<ul style="list-style-type: none"> characteristics of survivors and deceased COVID-19 hospitalised patients predictors of death 	<ul style="list-style-type: none"> Proportion Odds ratio 	<ul style="list-style-type: none"> 51% of deaths occurred in patients with diabetes. Diabetes was associated with a higher risk of death (OR 2.7, 95% CI: 1.8 - 3.9) 19% of deaths in patients with diabetes were new onset
Abraha HE, et al. [20]	Observational cohort	rural and urban hospitals in Northern Ethiopia	2,617 RT-PCR positive COVID-19 admitted patients	<ul style="list-style-type: none"> Characteristics of COVID-19 cases Predictors of mortality 	<ul style="list-style-type: none"> Proportion Relative risk 	<ul style="list-style-type: none"> 3.1% of all cases and 18.4% of severe cases had comorbid diabetes. Diabetes was associated with higher in-hospital mortality among COVID-19 patients (uRR: 7.73, 95% CI:

		October 2020 (Retrospective)				2.58-23.12
Kaswa R, et al. [21]	Observational cross-sectional study	Rural hospital, Eastern Cape South Africa March 2020 - July 2020 (Retrospective)	242 Hospitalised adult (>=18years) with laboratory-confirmed COVID-19	<ul style="list-style-type: none"> ▪ Characteristics of clinical outcomes 	<ul style="list-style-type: none"> ▪ Proportion of comorbidity 	<ul style="list-style-type: none"> ▪ Diabetes occurred in 36.8% of the cases ▪ Diabetes was the commonest comorbidity associated with higher mortality
Mbarga NF, et al. [22]	Observational cohort	Urban hospitals in Cameroon April 2020 - July 2020 (Prospective)	313 Patients admitted with suspected or confirmed COVID-19	<ul style="list-style-type: none"> ▪ Clinical characteristics of cases ▪ Predictors of COVID-19 severity 	<ul style="list-style-type: none"> ▪ Proportion ▪ Odds ratio 	<ul style="list-style-type: none"> ▪ 5.8% of cases had diabetes ▪ Diabetes was associated with increased COVID-19 severity (OR: 4.05, 95% CI 1.12,14.15; $p=0.01$)
Kwaghe VG, et al. [23]	Observational cross-sectional study	Urban hospital in Abuja, Nigeria March 2020 June 2020 (Retrospective)	200 admitted COVID-19 patients	<ul style="list-style-type: none"> ▪ Characteristics of cases 	<ul style="list-style-type: none"> ▪ Proportion 	<ul style="list-style-type: none"> ▪ 18.5% of the cases had diabetes
Leulseged TW, et al. [24]	Observational case-control	Urban hospital in Ethiopia June 2020 - September 2020 (Retrospective)	COVID-19 admitted patients Case =49 (death) Controls = 98 (recovered)	<ul style="list-style-type: none"> ▪ Predictors of clinical outcomes 	<ul style="list-style-type: none"> ▪ Proportion ▪ Odds ratio 	<ul style="list-style-type: none"> ▪ Having diabetes was associated with higher death outcomes than those with no diabetes (53.3% vs 46.7%, $p=0.001$) ▪ Diabetes patients exhibited higher odds of dying compared to those with no diabetes (AOR:3.26, 95% CI:1.35,7.87), $p=<0.01$.

Brey Z, et al. [25]	Observational cross-sectional study	Urban community setting in Cape Town, South Africa (Retrospective)	2,500 community health workers	<ul style="list-style-type: none"> Home delivery of medication for chronic disease patients 	<ul style="list-style-type: none"> Effectiveness Challenges and threats 	<ul style="list-style-type: none"> 46.2% of the delivery target was achieved The intervention was affected by incomplete, outdated and missing patient records and failure to reach registered phone contacts. Perceived opportunities were improved relationships of community health workers with linkage facilities and improved risk factor tracking. Perceived threats were stigma associated with home delivery
Abate HK, et al. [26]	Observational cross-sectional study	Rural and urban hospitals in Ethiopia August 2020 - September 2020 (Prospective)	576 adult type 2 diabetes patients	<ul style="list-style-type: none"> Predictors of adherence to exercise recommendations 	<ul style="list-style-type: none"> Proportion Odds ratio 	<ul style="list-style-type: none"> 26.4% only adhered to physical exercise recommendations. Rural residence was associated with higher odds of adherence to physical exercise recommendations (AOR: 1.95, 95% CI: 1.16,3.27, $p<0.05$) Being female was associated with higher odds of physical exercise adherence (AOR: 1.86, 95%CI, 1.27-2.72, $p<0.01$)
Bepouka BI, et al. [27]	Observational cohort	Urban hospital in Kinshasa, Democratic Republic of Congo March 2020 - June 2020 (Retrospective)	141 hospitalised patients with RT-PCR confirmed COVID-19	<ul style="list-style-type: none"> Characteristics of cases Predictors of survival and mortality 	<ul style="list-style-type: none"> Proportion Survival rate 	<ul style="list-style-type: none"> 17% of COVID-19 hospitalised patients had diabetes. Patients with diabetes had reduced COVID-19 survival, $p=0.015$

Boulle, et al. [14]	Observational cohort	Rural and urban hospitals in West Cape Province, South Africa	3,460,932 patients with PCR-confirmed COVID-19	<ul style="list-style-type: none"> Predictors of COVID-19 death 	<ul style="list-style-type: none"> Hazard ratio 	<ul style="list-style-type: none"> Diabetes was associated with COVID-19 death with the risk of death increasing with higher HbA1c values: <7% (HR 1.44, 95% CI: 1.06-1.96, $p=0.02$), 7%<9% (HR 1.81, CI:1.39-2.35, $p<0.001$), $\geq 9\%$ (HR 1.60, CI: 1.27-2.0, $p<0.001$) all vs those without diabetes.
Poaty H, et al. [28]	Observational cross-sectional study	Urban hospital in The Congo	30 patients with pre-existing diabetes infected with SARS-CoV-2	<ul style="list-style-type: none"> Characteristics of COVID-19 death 	<ul style="list-style-type: none"> Proportion 	<ul style="list-style-type: none"> Diabetes patients with COVID-19 had a mortality rate of 36.7%
Ikram AS & Pillay S. [29]	Observational cohort	Urban hospital in KwaZulu Natal, South Africa	236 hospitalised patients >13years with laboratory-confirmed SARS-CoV 2 infection	<ul style="list-style-type: none"> Predictors of mortality 	<ul style="list-style-type: none"> Proportion Odds ratio 	<ul style="list-style-type: none"> 50% of those admitted with hyperglycaemia having no history of diabetes died 26.6% of those living with diabetes (pre-existing or newly diagnosed) died. patients presenting with admission hyperglycaemia had higher odds of death (OR:4.24, 95%CI:1.12-16) Patients with diabetes had higher odds of dying compared to those with diabetes (OR: 1.97, 95% CI:0.99-3.89)
Leulseged TW, et al. [30]	Observational cross-sectional study	Urban hospital in Ethiopia	686 patients admitted with RT-PCR confirmed diagnosis of	<ul style="list-style-type: none"> Characteristics of cases Predictors of COVID-19 severity 	<ul style="list-style-type: none"> Proportion Odds ratio 	<ul style="list-style-type: none"> 16.6% of cases had diabetes. Diabetes had higher odds of COVID-19 severity than those who had no diabetes (AOR: 3.93, 95% CI:

		(Prospective)	COVID-19			1.96,7.85)	<ul style="list-style-type: none"> ▪ 29.9% of the severe cases had diabetes
Leulseged TW, et al. [31]	Observational cohort	Rural and urban hospitals in Ethiopia	1,345 patients admitted with RT-PCR confirmed COVID-19	<ul style="list-style-type: none"> ▪ Characteristics of cases ▪ Predictors of recovery 	<ul style="list-style-type: none"> ▪ Proportion ▪ Odds ratio 		<ul style="list-style-type: none"> ▪ 13.7% of cases had diabetes. ▪ Diabetes had a higher median duration of recovery (15 days) than those with no diabetes. ▪ Having diabetes was associated with 45.1% (p=0.005) lower odds of achieving clinical recovery compared to those without diabetes (AOR=0.549, 95% CI:0.337,0.894; p=<0.05).
Adjei P, et al. [32]	Observational cross-sectional study	Urban hospital in Accra, Ghana	50 hospital-admitted COVID-19 diagnosed patients	<ul style="list-style-type: none"> ▪ Clinical characteristics 	<ul style="list-style-type: none"> ▪ Proportion 		<ul style="list-style-type: none"> ▪ 42% of cases had diabetes. ▪ 90.5% of those with complications had diabetes. ▪ 23.8% of those with diabetes died
van der Westhuizen JN, et al. [33]	Observational cross-sectional study	Rural hospital in Western Cape Province, South Africa	1,447 patients admitted with confirmed COVID-19 and pre-existing or newly diagnosed diabetes	<ul style="list-style-type: none"> ▪ Characteristics of cases ▪ Predictors of death 	<ul style="list-style-type: none"> ▪ Proportion ▪ Odds ratio 		<ul style="list-style-type: none"> ▪ 86.5% had HbA1c >7%, median (IQR): 10% (8-12%). ▪ Being male (OR=2.05, 95%CI=1.07,3.93) and on insulin (OR=2.25, 95% CI=1.05,4.85) was associated with higher odds of death
Delobelle AP, et al. [34]	Observational cross-sectional study	Urban primary settings in South Africa	Facility workers = 09 Community-	<ul style="list-style-type: none"> ▪ Appraisal of care and management 	<ul style="list-style-type: none"> ▪ Impact 		<ul style="list-style-type: none"> ▪ Cancellation of routine non-communicable disease clinic services and chronic patient 'clubs'

		October 2020 - November 2020 (Prospective)	based workers = 11 Patient with type 2 diabetes and other NCD = 08			<ul style="list-style-type: none"> ▪ Reduced availability of healthcare workforce ▪ Introduction of clinic booking for clinics that improved clinic congestion. ▪ Home delivery of medication using community health workers was adopted to decongest health facilities. ▪ Improved performance of community health workforce ▪ Patient stigma associated with patient home visits and deliveries. ▪ General increase in workload among the health workforce. ▪ General decrease in the number of NCD patients visiting the facility compared with prior to COVID-19 period. ▪ Higher proportion of patients with uncontrolled diabetes.
Crankson S, et al. [35]	Observational cross-sectional study	Urban hospital in Ghana March 2020 - August 2021 (Retrospective)	2,334 PCR confirmed COVID-19 patients	<ul style="list-style-type: none"> ▪ Characteristics of cases ▪ Predictors of long COVID and hospitalisation 	<ul style="list-style-type: none"> ▪ Proportion ▪ Correlation 	<ul style="list-style-type: none"> ▪ Comorbid diabetes occurred in 2% of patients ▪ Long COVID occurred in 4.3% of persons with diabetes ▪ Diabetes was associated with longer LOS (B=1.37, 95% CI=0.99-1.88, p <0.05)
Ephraim RKD, et al. [36]	Observational cross-sectional study	Rural and urban hospitals in Cape Coast, Ghana	157 diabetes patients aged 20 years and	<ul style="list-style-type: none"> ▪ Characteristics of cases 	<ul style="list-style-type: none"> ▪ Proportion 	<ul style="list-style-type: none"> ▪ 57.3% of patients had known complications including retinopathy (36.3%) ▪ Family, friends and close relatives

		June 2020 - September 2020 (Prospective)	over			<ul style="list-style-type: none"> were the popular form of social support (79.6%) for diabetes patients, followed by diabetes teams (61.2%) fellow patients with diabetes (61.2%), social media (56.7%) and work/school mates (52.9%) ▪ Reduced frequency of meals was reported in 42% of the patients
Habineza JC, et al. [37]	Observational cross-sectional study	Rural and urban communities in Rwanda	52 young adults with type 1 diabetes	<ul style="list-style-type: none"> ▪ Pandemic experiences and challenges ▪ Coping mechanisms 	<ul style="list-style-type: none"> ▪ Proportion ▪ Experiences 	<ul style="list-style-type: none"> ▪ 80.8% reported a drop in family income; 57.7% reported a reduction in meal frequency; 43.1% reported reduced physical activity ▪ Hypoglycaemia was the major acute complication (87.5%) ▪ Access to diabetes management supplies during the COVID-19 pandemic did not significantly differ from pre-COVID-19. ▪ 81.8% increase in patients accessing healthcare by foot.
Baguma S, et al. [38]	Observational cohort	Urban Hospital in Northern Uganda	664 hospitalised patients with confirmed COVID-19	<ul style="list-style-type: none"> ▪ Characteristics of cases ▪ Predictors of mortality 	<ul style="list-style-type: none"> ▪ Proportion ▪ Odds ratio 	<ul style="list-style-type: none"> ▪ 34.4% of deaths occurred in patients with diabetes. ▪ Diabetes was associated with higher odds of death compared to those who had no diabetes (AOR=9.014, 95% CI=1.726 - 47.067)
Iroungou BA, et al. [39]	Observational cross-sectional study	Urban hospital in Lebrville, Gabon	837 COVID-19 hospitalised patients	<ul style="list-style-type: none"> ▪ Characteristics of severe COVID-19 	<ul style="list-style-type: none"> ▪ Proportion 	<ul style="list-style-type: none"> ▪ 16.1% patients with a history of diabetes had severe COVID-19

(Retrospective)						
Awucha NE, et al. [40]	Observational cross-sectional study	Rural and urban community settings in Nigeria May 2020 - June 2020 (Prospective)	374 persons aged 15 years and older	<ul style="list-style-type: none"> Impact on essential medicine access 	<ul style="list-style-type: none"> Proportion 	<ul style="list-style-type: none"> 28.1% had a known history of diabetes The proportion of patients with difficulty in accessing essential medicines during the COVID-19 pandemic was significantly higher than before the pandemic (29.6% vs 5.6%, $p < 0.001$) 52.2% decrease in hospital visits for medicines
Kaswa RP. & Meel B. [41]	Observational cross-sectional study	Urban hospital in Eastern Cape, South Africa July 2020 - January 2021 (Retrospective)	100 patients who died of COVID-19	<ul style="list-style-type: none"> Characteristics of COVID-19 deaths 	<ul style="list-style-type: none"> Proportion 	<ul style="list-style-type: none"> 37% of patients had diabetes
Usui R, Kanamori S, Aomori M. & Watabe S. [42]	Observational cross-sectional study	Rural and urban hospitals in Cote d'Ivoire March 2020 - July 2020 (Retrospective)	67 COVID-19 infected persons	<ul style="list-style-type: none"> Comorbidities associated with COVID-19 deaths 	<ul style="list-style-type: none"> Proportion 	<ul style="list-style-type: none"> 45% of COVID-19 deaths occurred in patients with diabetes
Tagoe ET, Nonvignon J, van Der Meer R,	Observational cross-sectional study	Rural and urban hospitals in Ghana November 2020 - February 2021	18 healthcare professionals and health facility administrators	<ul style="list-style-type: none"> COVID-19 impact on diabetes service delivery 	<ul style="list-style-type: none"> Impact 	<p>Themes:</p> <ul style="list-style-type: none"> high medicine and service costs and medicine shortages (disruption in supply chain, rationing, increased pricing of medicines)

Megiddo I, & Godman B. [13]	(Prospective)	rs		<ul style="list-style-type: none"> ▪ poor patient information management (substandard anthropometric procedures, increase in records with missing data, misplacement of patient record files) ▪ few trained healthcare providers (COVID-19 treatment prioritisation, patient rejection of referrals, high patient load) ▪ low healthcare provider motivation (unsupportive management) ▪ service organisation challenges (extended patient reviews, clinic overcrowding, increased clinic waiting times) ▪ national health policy-related concerns (policy restrictions could not allow flexibility in planning and cost sharing) 	
Sikhosana LM, Jassat W & Makatini Z. [43]	Observational cross-sectional study	Rural and urban hospitals in Gauteng, South Africa	1,861 SARS CoV 2 admitted patients	<ul style="list-style-type: none"> ▪ characteristics of cases ▪ Proportion 	<ul style="list-style-type: none"> ▪ 21.6% of cases had diabetes
Elijah MI, et al. [44]	Observational cohort	Rural and urban hospitals in Kenya	1,792 admitted COVID-19 patients	<ul style="list-style-type: none"> ▪ Predictors of hospitalisation and survival ▪ Prevalence of diabetes comorbidity ▪ Proportion ▪ Odds ratio 	<ul style="list-style-type: none"> ▪ 5.4% cases had diabetes ▪ Diabetes was a significant predictor of ICU admissions (aOR: 3.30, 95%CI: 1.94 - 560, p<0.0001) ▪ Diabetes was significantly associated with less survival probability compared to those without diabetes

(p<0.0001)						
Hardy OY, et al. [45]	Observational cross-sectional study	Urban hospital in Ghana March 2020 - October 2020 (Retrospective)	175 adult patients hospitalised with COVID-19	<ul style="list-style-type: none"> ▪ Prevalence of comorbid diabetes ▪ Predictors of hospitalisation 	<ul style="list-style-type: none"> ▪ Proportion ▪ Correlation 	<ul style="list-style-type: none"> ▪ 36.6% patients had type 2 diabetes ▪ No significant difference in COVID-19 severity and duration of hospitalisation between patients with diabetes and those without
Huluka KD, et al. [46]	Observational cross-sectional study	Urban hospital in Addis Ababa, Ethiopia March 2020 - September 2020 (Retrospective)	463 SARS CoV-2 positive patients aged ≥18	<ul style="list-style-type: none"> ▪ Clinical characteristics of cases 	<ul style="list-style-type: none"> ▪ Proportion 	<ul style="list-style-type: none"> ▪ 20.7% of cases had diabetes. ▪ 33.1 % of those who experienced severe COVID-19 had diabetes. ▪ 35.8% of COVID-19 deaths had diabetes
Nyasulu SP, et al. [47]	Observational cross-sectional study	Urban hospital in South Africa March 2020 - November 2020 (Prospective)	413 ICU admitted COVID-19 patients aged ≥18	<ul style="list-style-type: none"> ▪ Characteristics of cases and outcomes 	<ul style="list-style-type: none"> ▪ Proportion 	<ul style="list-style-type: none"> ▪ 51% of patients had comorbid diabetes. ▪ 66% of patients with comorbid diabetes died
Solanki G, et al. [48]	Observational cross-sectional study	Rural and urban communities in South Africa March 2020 - June 2021 (Retrospective)	188,292 private health insurance patients who tested positive for COVID-19	<ul style="list-style-type: none"> ▪ Risk of hospitalisation 	<ul style="list-style-type: none"> ▪ Odds ratio 	<ul style="list-style-type: none"> ▪ Diabetes was associated with high risk for hospitalisation (OR 3.6; 95% CI 3.27 - 3.94)
Diarra M, et al. [49]	Observational cross-sectional study	Rural and urban hospitals in Senegal	67,608 patients	<ul style="list-style-type: none"> ▪ Clinical characteristics ▪ Predictors of mortality 	<ul style="list-style-type: none"> ▪ Proportion ▪ Relative risk 	<ul style="list-style-type: none"> ▪ 38.2% of cases had diabetes ▪ Relative risk for COVID-19 mortality was high in persons with comorbid diabetes (aRR=1.31, 95%CI=0.77-

		March 2020 - October 2020 (Prospective)				2.23, $p < 0.001$)
Tolossa T, et al. [50]	Observational cohort	Urban hospital western Ethiopia September 2020 - June 2021 (Retrospective)	304 severe COVID-19 hospital-admitted patients	<ul style="list-style-type: none"> ▪ Clinical characteristics ▪ Predictors of onset diabetes 	<ul style="list-style-type: none"> ▪ Proportion ▪ Hazard ratio 	<ul style="list-style-type: none"> ▪ Incidence of diabetes among patients was 14.5%. ▪ Overall diabetes incidence rate at the end of follow-up (34 days) was 13.7/1,000 person day's observation (95% CI 10.2, 18.4) ▪ Median occurrence of diabetes was 11 days (95% CI: 7, 13) ▪ Risk of developing diabetes increased for the first 20 days and was constant thereafter (Kaplan-Meier survival estimate) ▪ Predictors of Diabetes included older age >41 years (AHR = 2.54, 95% CI: 1.15, 5.57, compared to <25years, $p=0.02$), residing in urban settings (AHR = 2.49, 95% CI: 1.12, 5.52, compared to rural, $p=0.02$), being admitted within 48 hours of clinical manifestation compared to >48hours (0.49, 95% CI: 0.23, 0.96 ref. ≤ 48hrs, $p=0.04$)
David JN, et al. [51]	Observational cross-sectional study	Rural community in South Africa September 2020 - December 2020 (Prospective)	544 type 2 diabetes patients attending routine care	<ul style="list-style-type: none"> ▪ Home delivery of medicines 	<ul style="list-style-type: none"> ▪ Impact of home delivery 	<ul style="list-style-type: none"> ▪ overall, HDM resulted in 0.46% reduction in HbA1c compared to non-HDM ($p < 0.01$) ▪ Patients perceived HDM as timesaving. ▪ Patients perceived HDM as reducing exposure to coronavirus infection

Sane HA, et al. [52]	Observational cross-sectional study	Urban hospitals in Addis Ababa, Ethiopia September 2020 - September 2021 (Retrospective)	244 COVID-19-admitted patients with diagnosed diabetes	<ul style="list-style-type: none"> Prevalence of new-onset diabetes Predictors of new-onset diabetes 	<ul style="list-style-type: none"> Proportion Odds ratio 	<ul style="list-style-type: none"> 31.1% of COVID-19 patients had onset Diabetes (95% CI: 25.4, 37.4) Males were more likely to develop new onset diabetes than females (aOR=2.9, 95%CI:1.2,7.1, p=0.018)
Jassat W, et al. [53]	Observational cross-sectional study	Rural and urban hospital in South Africa November 2020 - June 2021 (Prospective)	3,217 COVID-19 hospitalised patients	<ul style="list-style-type: none"> Prevalence of diabetes 	<ul style="list-style-type: none"> Proportion 	<ul style="list-style-type: none"> 26.6% had self-reported diabetes 7.3% of diabetes case were new diagnoses
Mengist B, Animut Z & Tolossa T. [54]	Observational cohort	Rural and urban hospitals in Northwest Ethiopia March 2020 - March 2021 (Retrospective)	552 COVID-19 hospitalised patients	<ul style="list-style-type: none"> Prevalence of diabetes Predictors of mortality 	<ul style="list-style-type: none"> Proportion Hazard ratio 	<ul style="list-style-type: none"> 4% of patients had comorbid diabetes. patients with diabetes had 8 times higher hazard mortality than those without diabetes (AHR: 8.1, 95% Ci:2.9, 22.4, $p<0.001$)

131

132

133 **Prevalence and incidence of DM among COVID-19 cases**

134 As shown in Table 2, comorbidity of DM and COVID-19 was very prevalent, with up to 51%
 135 pre-existing cases reported, and a mean (SD) figure of 23% (± 13.8). Prevalence as high as
 136 31.1% was also reported for new-onset DM among COVID-19 hospitalised cases, and a high
 137 incidence rate of 37/1,000 person days [50].

138 Table 2: Studies reporting on different COVID-19 outcome variables.

Outcome variable	Range or value	Study reference
Comorbidity of DM and COVID-19		
Incidence of DM in COVID-19 cases (per 1,000-person day's observation)	13.7	[50]
Prevalence of new-onset DM among COVID-19 cases	7.3% - 31.1%	[16,50,52,53]
Prevalence of DM among COVID-19 cases*	2.0% - 51.0%	[15–18,20–23,30–32,35,38,40,43,45–47,49,53–56]
COVID-19-related outcomes in DM patients		
Proportion of DM deaths attributed to COVID-19	5.3% - 66%	[17,19,24,28,29,32,33,42,46,47]
<i>DM risk for COVID-19 mortality (odds ratio, 95% CI)**</i>	1.30 – 9.0	[14–16,19,20,24,38,49,54]
Proportion of DM hospitalisation attributed to COVID-19***	17%	[27]
<i>DM risk for COVID-19 hospitalisation (odds ratio, 95% CI)**</i>	3.30 - 3.73	[16,35,48]
Proportion of DM-related COVID-19 severity	16.1% - 33.1%	[20,30,39,46]
<i>DM risk for COVID-19 severity (odds ratio, 95% CI)**</i>	1.30 - 4.05	[18,22,30]
Duration of hospitalisation of DM patients with COVID-19	4.7 - 15.0 days	[22,31]
Proportion of PLWD experiencing COVID-19 complications	4.3% - 90.5%	[32,35]
Predictors of COVID-19-related clinical outcomes in DM		
Predictors of COVID-19 mortality in PLWD (odds ratio, 95% CI)		
Age (per 5-year ageing interval)	1.13 - 1.37	[16]
Gender (Male)	1.50 - 2.04	[16,18,33]
Medication (Insulin)	1.49 - 2.25	[16,33]
Glycaemic control (HbA1c \geq 7%)	1.39 - 1.60	[14]
Predictors of COVID-19 hospitalisation in PLWD (odds ratio, 95% CI)		
Age (per 5-year ageing interval)	1.13 - 1.17	[16]
Gender (Male)	1.29 - 1.54	[16]
Medication (Insulin)	1.24 - 1.57	[16]
Predictors of new-onset DM in COVID-19 patients (odds ratio, 95% CI)		
Age (>41years)	1.15 - 5.57	[50]

Gender (Male)	1.2 - 7.1	[52]
Residence (Urban)	1.12 - 5.52	[50]

139 *(mean=23% ±13.8%); ** compared to those with no diabetes; *** figure reported from single studies
 140 without confidence interval; HbA1c: Glycated Haemoglobin; CI: confidence interval

141 **COVID-19-related outcomes of DM and their predictors**

142 As shown in Table 2, mortality, hospitalisation, severity, and complications were the major
 143 outcomes related to COVID-19 in DM. The proportions of COVID-19-attributed mortality
 144 [17,19,24,28,29,32,33,42,46,47], hospitalisation [27], and severity [20,30,39,46] for PLWD
 145 were noticeable to high across the studies. The major predictors of COVID-19-related mortality
 146 and hospitalisation in PLWD were age, gender, DM treatment, and glycaemic control. For
 147 every 5-year age interval, being male, insulin treatment and HbA1c ≥7.0% were
 148 independently associated with higher odds for both COVID-19-related mortality [14,16,18,33]
 149 and hospitalisation [16]. On the other hand, new-onset DM, defined as DM diagnosed in
 150 hospitalised COVID-19 patients with prior normoglycaemia, was associated with age over 41
 151 years, male gender and urban residence [50,52].

152 **Impact of the COVID-19 pandemic on DM care**

153 Using an inductive thematic approach, we constructed three major themes from qualitative,
 154 mixed methods studies and open-ended quantitative results. The findings were thematically
 155 categorised as patient-related health management challenges, DM care service delivery
 156 challenges, and reorganisation of DM care delivery (S3 Themes). Table 3 presents a summary
 157 of studies that reported on each theme category.

158 Table 3: Studies reporting COVID-19 pandemic's impact on various aspects of DM care
 159 management.

Major theme	Sub-theme	Reference
Patient-related health management challenges	Self-management challenges	[15,33,36,37]
	Affordability challenges	[13,37]
	Health service accessibility challenges	[13,37,51]
DM care service delivery	Health workforce challenges	[13,34]

challenges	Healthcare infrastructure challenges	[13]
	Health information challenges	[25]
	Medicines and medical supplies	[13]
Re-organisation of DM care delivery	Patient-level reorganisation of care access	[25,34,51]
	Clinic-level reorganisation of management	[34]
	Community-level re-organisation of community health worker services	[25,34,51]

160

161 **Patient-related health management challenges**

162 The three sub-themes that emerged under patient-related health management challenges
163 were, self-management challenges, affordability challenges, and health service accessibility
164 challenges. Self-management challenges reported among PLWD during the COVID-19
165 pandemic include reduced daily meal frequency [36,37], inadequate physical activity [26,37],
166 and worsening glycaemic control [15,33,34]. Affordability challenges were related to increased
167 costs of medicines [13] and reduced individual or household income [37]. PLWD also
168 experienced health service accessibility challenges reported as increased clinic waiting time
169 [13] and limited transport means to healthcare facilities [16,51]. Type 1 DM-specific challenges
170 were limited food access, reduced affordability of living costs and accessibility of DM care
171 services [37].

172 **DM care service delivery challenges**

173 Four sub-themes emerged under DM care delivery challenges, namely, health workforce
174 challenges [13,34], healthcare infrastructure challenges [13,34], health information
175 management challenges [13,25], and medicines and medical supplies [13]. Health workforce
176 challenges were characterised by health workers' hesitancy towards work and the limited
177 number of available DM specialists. This resulted in fewer active health workers at health
178 facilities that increased workload [13,34]. At the same time, inadequate healthcare
179 infrastructure limited available physical clinic space due to overwhelming patient numbers

180 [13,34]. The COVID-19 pandemic was also characterised by poor management of health
181 information and medical records attributed to the heavy workload of health workers and the
182 fear of the risk of cross-infection while collecting patient data [13,25]. Additionally, the
183 pandemic worsened shortages of medicine and medical supplies at health facilities [13].

184 **Reorganisation of DM care delivery**

185 Four sub-themes, as shown in Table 3, were categorised under the reorganisation of DM care
186 delivery as a result of the pandemic, namely, patient-level reorganisation of care access
187 [25,34,51], clinic-level reorganisation in management [34], and community-level reorganisation
188 of community health worker services [25,34,51]. The reorganisation of DM care delivery was
189 in response to the challenges patients and healthcare facilities faced in accessing and
190 delivering DM care services. The interventions included delivery of patient medicines to their
191 homes through their community health workers [25,34,51], which addressed the risk of
192 infection and mitigated the health facility accessibility challenges faced by patients during
193 lockdowns [34]. At clinic level, routine non-communicable disease 'walk-in' clinics were
194 replaced with a clinic booking system to manage patient appointments and control clinic
195 patient numbers [34]. At the community level, community health workers were empowered to
196 monitor and follow up on patients with non-communicable diseases, including DM, aimed at
197 reducing the workload of health facility staff [25,34,51].

198 **Discussion**

199 Our scoping review of 42 articles highlighted COVID-19's impact on DM outcomes and care in
200 SSA. It also lays down existing gaps in knowledge and research. To the best of our knowledge,
201 this is the first systematic scoping review in SSA to investigate outcomes of DM with COVID-19
202 and the pandemic's effect on DM care. Our results show an inequitable representation in DM
203 research in countries of SSA, with research outputs mainly contributed by South Africa.

204 Overall, our scoping review shows that COVID-19 increased the risk of mortality and
205 hospitalisation in PLWD, which were associated with older age, poor glycaemic control, insulin
206 use and being male. These risk factors have also been reported in the US [57], China [58] and
207 the UK [59]. We observed that PLWD had up to nine times higher risk of death, more than
208 three times higher risk of hospitalisation and up to four times higher risk for severity due to
209 COVID-19 compared to those without DM. Notably, similar findings but with varying levels of
210 mortality and morbidity have been reported in China and the USA by Kumar et al. [60]. They
211 revealed higher odds of COVID-19-related mortality (2.16, 95% CI: 1.74-2.65) and severity
212 (2.75, 95% CI: 2.09-3.62) in PLWD than those without DM. COVID-19's impact on DM clinical
213 outcomes in SSA is significant and consistent with reports from the World Health Organization
214 that indicate COVID-19 is deadlier in PLWD in Africa due to the region's characteristic poor
215 glycaemic control [61,62]. Additionally, COVID-19 was associated with an increased risk of
216 developing new-onset DM, especially among hospitalised COVID cases over 41 years, males
217 and urban residents. We observed a DM incident rate of 13.7/1,000 person-days (the
218 equivalent of 5/1,000 person-years) and a prevalence of new-onset DM of up to 31% among
219 COVID-19 cases in SSA. This rate is, however, considerably lower than what has been reported
220 in the US (23-83/1,000 person-years) [63], England (37.2/1,000 person-years) [64] and China
221 (13.5/1,000 person-years) [65]. Whereas the variation in diabetes incidence among COVID-19
222 patients in SSA may be due to underreporting, COVID-19's epidemiological threat to the
223 growing burden of DM in SSA needs to be tracked.

224 As a pandemic, COVID-19 also impacted DM indirectly by causing disruptions in patient self-
225 management routines and delivery of DM services in SSA. As our scoping review highlights, this
226 impact manifested through challenges posed by instituted COVID-19 restrictions. For PLWD, we
227 observe that this negatively affected their dietary intake and engagement in physical activity
228 and limited their access to healthcare. The experience in SSA was however, in marked contrast
229 with reports from India [66] and the UK [67], which showed no notable negative COVID-19

230 impact on access to essential services among PLWD. This stark variation may be explained by
231 the different countries' approaches to containing COVID-19, which in most SSA countries
232 mainly targeted geographical containment, closure of non-essential services and prohibition of
233 gatherings [68]. These unprecedented approaches created blockades to accessibility and
234 affordability of various services, including health and social services [69–71]. On other
235 grounds, there was a considerable shortage of health workforce, physical infrastructure and
236 severe shortages of DM medicine and medical supplies. Whereas we acknowledge the pre-
237 existence of challenges in the health workforce, healthcare infrastructure and medical supplies
238 in SSA before the COVID-19 pandemic, the magnitude might have worsened during the
239 pandemic due to a shift in healthcare resource prioritisation toward COVID-19
240 [72][73][74][73,75].

241 Interestingly, we also observed from our scoping review that the pandemic presented some
242 opportunities for DM care innovation. For instance, the delivery of medicine to patient homes
243 implemented in South Africa reportedly reduced the risk of COVID-19 infection among PLWD,
244 mitigated DM care access challenges and ensured continued chronic patient follow-up [40].
245 Home delivery of medicine has also been reported to improve treatment adherence among
246 chronic disease patients in Rwanda, which shows its feasibility in other SSA countries [76]. The
247 pandemic, as demonstrated in South Africa, has also evidenced the value of integrating chronic
248 non-communicable disease prevention and care in the services of community health workers.
249 Additionally, clinic booking systems introduced to replace walk-in clinics in public health centres
250 were found to mitigate clinic overcrowding, reduce clinic waiting time, and provide better
251 doctor-to-patient time. These changes in the reorganisation of healthcare service delivery
252 proved vital in addressing many challenges posed by the COVID-19 pandemic and offer lessons
253 to policy and practice in future planning.

254 **Gaps in knowledge and research**

255 In our scoping review, we note various gaps in knowledge that can inform subsequent
256 research. Firstly, there is a gap in the published literature on the use of guidelines for
257 managing COVID-19 and DM in SSA countries, which would help evaluate their appropriateness
258 for future similar occurrences. Secondly, the studies in our scoping review did not report on
259 vaccine uptake or how the different 'waves' of COVID-19 infection influenced COVID-19
260 outcomes among PLWD. This would provide an understanding of the outcomes of PLWD across
261 evolving pandemic dynamics and health system interventions. Exploiting research opportunities
262 to address such gaps in knowledge can provide further and comprehensive understanding to
263 shape appropriate post-pandemic DM care approaches and health system preparedness in
264 addressing chronic care vulnerabilities during possible future pandemics.

265 **Limitations**

266 While this scoping review provides reliable information by scoping various research types and
267 sources, there are some limitations. Firstly, our scoping review only included articles published
268 in English. This may have limited studies published from non-English speaking countries within
269 SSA; therefore, some relevant studies may have been missed. However, considering what was
270 retrieved from most SSA countries, we predict this number to be likely minimal. Secondly, the
271 included studies were dominated by three countries, which may limit the generalisation of
272 findings to SSA. Thirdly, the studies were mainly conducted in the initial phase of the pandemic
273 in 2020, indicating that changes experienced after that may render some findings
274 unrepresentative of the post-2020 dynamics including the impact of emerging COVID-19
275 variants. Moreover, the limited disaggregation of data by studies in our scoping review,
276 especially age, gender and type of DM, limited the drawing of specific conclusions and
277 analyses. Finally, we only included peer-reviewed literature, which may have excluded some
278 valuable literature sources such as manuscripts, institutional reports and archives.

279 Nevertheless, this scoping review provided critical information and insights on how COVID-19
280 impacted PLWD and healthcare systems in SSA.

281 **Conclusions**

282 COVID-19 increased mortality and morbidity among PLWD and the occurrence of DM. In
283 addition, the pandemic worsened DM self-care and DM service delivery generally. Therefore,
284 further research in SSA is needed to understand the disease syndemism of pandemics such as
285 COVID-19 and DM to inform future management strategies and policy considerations.

286

287 **References**

- 288 1. Wang H, Paulson KR, Pease SA, Watson S, Comfort H, Zheng P, et al. Estimating excess
289 mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related
290 mortality, 2020–21. *Lancet*. 2022;399: 1513–1536. doi:10.1016/S0140-6736(21)02796-3
- 291 2. Post LA, Argaw ST, Jones C, Moss CB, Resnick D, Singh LN, et al. A SARS-CoV-2
292 Surveillance System in Sub-Saharan Africa: Modeling Study for Persistence and
293 Transmission to Inform Policy. *J Med Internet Res*. 2020;22: e24248. doi:10.2196/24248
- 294 3. Fu Y, Hu L, Ren H-W, Zuo Y, Chen S, Zhang Q-S, et al. Prognostic Factors for COVID-19
295 Hospitalized Patients with Preexisting Type 2 Diabetes. Merlotti D, editor. *Int J*
296 *Endocrinol*. 2022;2022: 1–13. doi:10.1155/2022/9322332
- 297 4. Hayden MR. An Immediate and Long-Term Complication of COVID-19 May Be Type 2
298 Diabetes Mellitus: The Central Role of β -Cell Dysfunction, Apoptosis and Exploration of
299 Possible Mechanisms. *Cells*. 2020;9: 2475. doi:10.3390/cells9112475
- 300 5. Landstra CP, de Koning EJP. COVID-19 and Diabetes: Understanding the
301 Interrelationship and Risks for a Severe Course. *Front Endocrinol (Lausanne)*. 2021;12.
302 doi:10.3389/fendo.2021.649525
- 303 6. Filip R, Gheorghita Puscaselu R, Anchidin-Norocel L, Dimian M, Savage WK. Global
304 Challenges to Public Health Care Systems during the COVID-19 Pandemic: A Review of
305 Pandemic Measures and Problems. *J Pers Med*. 2022;12: 1295.
306 doi:10.3390/jpm12081295
- 307 7. Topkar V. Interactions Between Diabetes And Covid-19: A Scoping Review. Yale
308 University. 2022. Available:
309 [https://elischolar.library.yale.edu/ysphtdl/2207?utm_source=elischolar.library.yale.edu%](https://elischolar.library.yale.edu/ysphtdl/2207?utm_source=elischolar.library.yale.edu%2Fysphtdl%2F2207&utm_medium=PDF&utm_campaign=PDFCoverPages)
310 [2Fysphtdl%2F2207&utm_medium=PDF&utm_campaign=PDFCoverPages](https://elischolar.library.yale.edu/ysphtdl/2207?utm_source=elischolar.library.yale.edu%2Fysphtdl%2F2207&utm_medium=PDF&utm_campaign=PDFCoverPages)

- 311 8. Khunti K, Aroda VR, Aschner P, Chan JCN, Del Prato S, Hambling CE, et al. The impact
312 of the COVID-19 pandemic on diabetes services: planning for a global recovery. *Lancet*
313 *Diabetes Endocrinol.* 2022;10: 890–900. doi:10.1016/S2213-8587(22)00278-9
- 314 9. IDF. *IDF Diabetes Atlas 10th Edition*. Brussels; 2021.
- 315 10. Cooke A, Smith D, Booth A. Beyond PICO. *Qual Health Res.* 2012;22: 1435–1443.
316 doi:10.1177/1049732312452938
- 317 11. Richardson S, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a
318 key to evidence-based decisions. *ACP J Club.* 1995;123.
- 319 12. World Bank. *FOCUS: Sub-Saharan Africa*. 2021 [cited 22 Feb 2024]. Available:
320 <https://openknowledge.worldbank.org/pages/focus-sub-saharan-africa>
- 321 13. Tagoe ET, Nonvignon J, van Der Meer R, Megiddo I, Godman B. Challenges to the
322 delivery of clinical diabetes services in Ghana created by the COVID-19 pandemic. *J*
323 *Health Serv Res Policy.* 2023;28: 58–65. doi:10.1177/13558196221111708
- 324 14. Boulle A, Davies M-A, Hussey H, Ismail M, Morden E, Vundle Z, et al. Risk Factors for
325 Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the
326 Western Cape Province, South Africa. *Clin Infect Dis.* 2021;73: e2005–e2015.
327 doi:10.1093/cid/ciaa1198
- 328 15. Mash RJ, Presence-Vollenhoven M, Adeniji A, Christoffels R, Doubell K, Eksteen L, et al.
329 Evaluation of patient characteristics, management and outcomes for COVID-19 at district
330 hospitals in the Western Cape, South Africa: descriptive observational study. *BMJ Open.*
331 2021;11: e047016. doi:10.1136/bmjopen-2020-047016
- 332 16. Dave JA, Tamuhla T, Tiffin N, Levitt NS, Ross IL, Toet W, et al. Risk factors for COVID-
333 19 hospitalisation and death in people living with diabetes: A virtual cohort study from
334 the Western Cape Province, South Africa. *Diabetes Res Clin Pract.* 2021;177: 108925.

- 335 doi:10.1016/j.diabres.2021.108925
- 336 17. van Hoving DJ, Hattingh N, Pillay SK, Lockey T, McAlpine DJ, Nieuwenhuys K, et al.
337 Demographics and clinical characteristics of hospitalised patients under investigation for
338 COVID-19 with an initial negative SARS-CoV-2 PCR test result. *African J Emerg Med.*
339 2021;11: 429–435. doi:10.1016/j.afjem.2021.09.002
- 340 18. Ratshikhopha E, Muvhali M, Naicker N, Tlotleng N, Jassat W, Singh T. Disease Severity
341 and Comorbidities among Healthcare Worker COVID-19 Admissions in South Africa: A
342 Retrospective Analysis. *Int J Environ Res Public Health.* 2022;19: 5519.
343 doi:10.3390/ijerph19095519
- 344 19. Claassen N, van Wyk G, van Staden S, Basson MMD. Experiencing COVID-19 at a large
345 district level hospital in Cape Town: A retrospective analysis of the first wave. *South*
346 *African J Infect Dis.* 2022;37. doi:10.4102/sajid.v37i1.317
- 347 20. Abraha HE, Gessesse Z, Gebrecherkos T, Kebede Y, Weldegiargis AW, Tequare MH, et
348 al. Clinical features and risk factors associated with morbidity and mortality among
349 patients with COVID-19 in northern Ethiopia. *Int J Infect Dis.* 2021;105: 776–783.
350 doi:10.1016/j.ijid.2021.03.037
- 351 21. Kaswa R, Yogeswaran P, Cawe B. Clinical outcomes of hospitalised COVID-19 patients at
352 Mthatha Regional Hospital, Eastern Cape, South Africa: A retrospective study. *South*
353 *African Fam Pract.* 2021;63. doi:10.4102/safp.v63i1.5253
- 354 22. Fouda Mbarga N, Epee E, Mbarga M, Ouamba P, Nanda H, Nkengni A, et al. Clinical
355 profile and factors associated with COVID-19 in Yaounde, Cameroon: A prospective
356 cohort study. Zivkovic AR, editor. *PLoS One.* 2021;16: e0251504.
357 doi:10.1371/journal.pone.0251504
- 358 23. Kwaghe VG, Habib ZG, Akor AA, Thairu Y, Bawa A, Adebayo FO, et al. Clinical

- 359 characteristics and outcome of the first 200 patients hospitalized with coronavirus
360 disease-2019 at a treatment center in Abuja, Nigeria: a retrospective study. *Pan Afr Med*
361 *J.* 2022;41: 118. doi:10.11604/pamj.2022.41.118.26594
- 362 24. Leulseged TW, Maru EH, Hassen IS, Zewde WC, Chamiso NH, Abebe DS, et al.
363 Predictors of death in severe COVID-19 patients at millennium COVID-19 care center in
364 Ethiopia: a case-control study. *Pan Afr Med J.* 2021;38.
365 doi:10.11604/pamj.2021.38.351.28831
- 366 25. Brey Z, Mash R, Goliath C, Roman D. Home delivery of medication during Coronavirus
367 disease 2019, Cape Town, South Africa: Short report. *African J Prim Heal Care Fam Med.*
368 2020;12. doi:10.4102/phcfm.v12i1.2449
- 369 26. Abate HK, Ferede YM, Mekonnen CK. Adherence to physical exercise recommendations
370 among type 2 diabetes patients during the COVID-19 pandemic. *Int J Africa Nurs Sci.*
371 2022;16: 100407. doi:10.1016/j.ijans.2022.100407
- 372 27. Bepouka BI, Mandina M, Makulo JR, Longokolo M, Odio O, Mayasi N, et al. Predictors of
373 mortality in COVID-19 patients at Kinshasa University Hospital, Democratic Republic of
374 the Congo (from March to June 2020). *Pan Afr Med J.* 2020;37.
375 doi:10.11604/pamj.2020.37.105.25279
- 376 28. Poaty H, Emergence Poaty G, NDziessi G, Godefroy Ngakeni E, Doukaga Makouka T,
377 Soussa Gadoua R, et al. Diabetes and COVID-19 in Congolese patients. *Afr Health Sci.*
378 2021;21: 1100–1106. doi:10.4314/ahs.v21i3.18
- 379 29. Ikram A, Pillay S. Hyperglycaemia, diabetes mellitus and COVID-19 in a tertiary hospital
380 in KwaZulu-Natal. *J Endocrinol Metab Diabetes South Africa.* 2022;27: 32–41.
381 doi:10.1080/16089677.2021.1997427
- 382 30. Leulseged TW, Abebe KG, Hassen IS, Maru EH, Zewde WC, Chamiso NW, et al. COVID-

- 383 19 disease severity and associated factors among Ethiopian patients: A study of the
384 millennium COVID-19 care center. Taghizadeh-Hesary F, editor. PLoS One. 2022;17:
385 e0262896. doi:10.1371/journal.pone.0262896
- 386 31. Leulseged TW, Hassen IS, Maru EH, Zewsde WC, Chamiso NW, Bayisa AB, et al.
387 Characteristics and outcome profile of hospitalized African patients with COVID-19: The
388 Ethiopian context. Mossong J, editor. PLoS One. 2021;16: e0259454.
389 doi:10.1371/journal.pone.0259454
- 390 32. Adjei P, Afriyie-Mensah J, J. Ganu V, Puplampu P, Opoku-Asare B, Dzefi-Tetty K, et al.
391 Clinical characteristics of COVID-19 patients admitted at the Korle-Bu Teaching Hospital,
392 Accra, Ghana. Ghana Med J. 2020;54: 33–38. doi:10.4314/gmj.v54i4s.6
- 393 33. Van der Westhuizen J-N, Hussey N, Zietsman M, Salduker N, Manning K, Dave JA, et al.
394 Low mortality of people living with diabetes mellitus diagnosed with COVID-19 and
395 managed at a field hospital in Western Cape Province, South Africa. South African Med
396 J. 2021;111: 961. doi:10.7196/SAMJ.2021.v111i10.15779
- 397 34. Delobelle PA, Abbas M, Datay I, De Sa A, Levitt N, Schouw D, et al. Non-communicable
398 disease care and management in two sites of the Cape Town Metro during the first wave
399 of COVID-19: A rapid appraisal. African J Prim Heal Care Fam Med. 2022;14.
400 doi:10.4102/phcfm.v14i1.3215
- 401 35. Crankson S, Pokhrel S, Anokye NK. Determinants of COVID-19-Related Length of
402 Hospital Stays and Long COVID in Ghana: A Cross-Sectional Analysis. Int J Environ Res
403 Public Health. 2022;19: 527. doi:10.3390/ijerph19010527
- 404 36. Ephraim RKD, Duah E, Nkansah C, Amoah S, Fosu E, Afrifa J, et al. Psychological impact
405 of COVID-19 on diabetes mellitus patients in Cape Coast, Ghana: a cross-sectional
406 study. Pan Afr Med J. 2021;40: 76. doi:10.11604/pamj.2021.40.76.26834

- 407 37. Habineza JC, James S, Sibomana L, Klatman E, Uwingabire E, Maniam J, et al. Perceived
408 impact of the COVID-19 pandemic on young adults with type 1 diabetes in Rwanda. *Pan*
409 *Afr Med J.* 2021;40. doi:10.11604/pamj.2021.40.252.28899
- 410 38. Baguma S, Okot C, Alema NO, Apiyo P, Layet P, Acullu D, et al. Factors Associated With
411 Mortality Among the COVID-19 Patients Treated at Gulu Regional Referral Hospital: A
412 Retrospective Study. *Front Public Heal.* 2022;10. doi:10.3389/fpubh.2022.841906
- 413 39. Iroungou BA, Mangouka LG, Bivigou-Mboumba B, Moussavou-Boundzanga P, Obame-
414 Nkoghe J, Nzigou Boucka F, et al. Demographic and Clinical Characteristics Associated
415 With Severity, Clinical Outcomes, and Mortality of COVID-19 Infection in Gabon. *JAMA*
416 *Netw Open.* 2021;4: e2124190. doi:10.1001/jamanetworkopen.2021.24190
- 417 40. Emmanuel Awucha N, Chinelo JaneFrances O, Chima Meshach A, Chiamaka Henrietta J,
418 Ibilolia Daniel A, Esther Chidiebere N. Impact of the COVID-19 Pandemic on Consumers'
419 Access to Essential Medicines in Nigeria. *Am J Trop Med Hyg.* 2020;103: 1630–1634.
420 doi:10.4269/ajtmh.20-0838
- 421 41. Kaswa RP, B Meel. A Study on the Characteristic Features of Covid-19 Deaths in a
422 Regional Hospital in Mthatha in the Eastern Cape, South Africa. *Indian J Forensic Med*
423 *Toxicol.* 2021;16: 1554–1559. doi:10.37506/ijfmt.v16i1.17723
- 424 42. Usui R, Kanamori S, Aomori M, Watabe S. Analysis of COVID-19 mortality in patients
425 with comorbidities in Côte d'Ivoire. *J Public Health Africa.* 2022;13.
426 doi:10.4081/jphia.2022.1748
- 427 43. Sikhosana ML, Jassat W, Makatini Z. Characteristics of hospitalised COVID-19 patients
428 during the first two pandemic waves, Gauteng. *South African J Infect Dis.* 2022;37.
429 doi:10.4102/sajid.v37i1.434
- 430 44. Elijah IM, Amsalu E, Jian X, Cao M, Mibei EK, Kerosi DO, et al. Characterization and

- 431 determinant factors of critical illness and in-hospital mortality of COVID-19 patients: A
432 retrospective cohort of 1,792 patients in Kenya. *Biosaf Heal.* 2022;4: 330–338.
433 doi:10.1016/j.bsheal.2022.06.002
- 434 45. Hardy YO, Libhaber E, Ofori E, Amenuke DAY, Kontoh SA, Dankwah JA, et al. Clinical
435 and laboratory profile and outcomes of hospitalized COVID-19 patients with type 2
436 diabetes mellitus in Ghana – A single-center study. *Endocrinol Diabetes Metab.* 2023;6.
437 doi:10.1002/edm2.391
- 438 46. Huluka DK, Etissa EK, Ahmed S, Abule HA, Getachew N, Abera S, et al. Clinical
439 Characteristics and Treatment Outcomes of COVID-19 Patients at Eka Kotebe General
440 Hospital, Addis Ababa, Ethiopia. *Am J Trop Med Hyg.* 2022;107: 252–259.
441 doi:10.4269/ajtmh.21-1270
- 442 47. Nyasulu PS, Ayele BT, Koegelenberg CF, Irusen E, Lalla U, Davids R, et al. Clinical
443 characteristics associated with mortality of COVID-19 patients admitted to an intensive
444 care unit of a tertiary hospital in South Africa. Aouissi HA, editor. *PLoS One.* 2022;17:
445 e0279565. doi:10.1371/journal.pone.0279565
- 446 48. Solanki G, Wilkinson T, Bansal S, Shiba J, Manda S, Doherty T. COVID-19 hospitalization
447 and mortality and hospitalization-related utilization and expenditure: Analysis of a South
448 African private health insured population. Kuo RN, editor. *PLoS One.* 2022;17:
449 e0268025. doi:10.1371/journal.pone.0268025
- 450 49. Diarra M, Barry A, Dia N, Diop M, Sonko I, Sagne S, et al. First wave COVID-19
451 pandemic in Senegal: Epidemiological and clinical characteristics. Mossong J, editor.
452 *PLoS One.* 2022;17: e0274783. doi:10.1371/journal.pone.0274783
- 453 50. Tolossa T, Lema M, Wakuma B, Turi E, Fekadu G, Mulisa D, et al. Incidence and
454 predictors of diabetes mellitus among severe COVID-19 patients in western Ethiopia: a

- 455 retrospective cohort study. *J Endocrinol Metab Diabetes South Africa*. 2023;28: 42–48.
456 doi:10.1080/16089677.2022.2144016
- 457 51. David NJ, Bresick G, Moodaley N, Von Pressentin KB. Measuring the impact of
458 community-based interventions on type 2 diabetes control during the COVID-19
459 pandemic in Cape Town – A mixed methods study. *South African Fam Pract*. 2022;64.
460 doi:10.4102/safp.v64i1.5558
- 461 52. Sane AH, Mekonnen MS, Tsegaw MG, Zewde WC, Mesfin EG, Beyene HA, et al. New
462 Onset of Diabetes Mellitus and Associated Factors among COVID-19 Patients in COVID-
463 19 Care Centers, Addis Ababa, Ethiopia 2022. Kretchy I, editor. *J Diabetes Res*.
464 2022;2022: 1–9. doi:10.1155/2022/9652940
- 465 53. Jassat W, Mudara C, Vika C, Dryden M, Masha M, Arendse T, et al. Undiagnosed
466 comorbidities among individuals hospitalised with COVID-19 in South African public
467 hospitals. *South African Med J*. 2022;112: 747–752.
468 doi:10.7196/SAMJ.2022.v112i9.16417
- 469 54. Mengist B, Animut Z, Tolossa T. Incidence and predictors of mortality among COVID-19
470 patients admitted to treatment centers in North West Ethiopia; A retrospective cohort
471 study, 2021. *Int J Africa Nurs Sci*. 2022;16: 100419. doi:10.1016/j.ijans.2022.100419
- 472 55. Kaswa P, Meel B. A Study on the Characteristic Features of Covid-19 Deaths in a
473 Regional Hospital in Mthatha in the Eastern Cape, South Africa. *Indian J Forensic Med*
474 *Toxicol*. 2022;16. doi:10.37506/ijfamt.v16i1.17723
- 475 56. Elijah IM, Amsalu E, Jian X, Cao M, Mibei EK, Kerosi DO, et al. Characterization and
476 determinant factors of critical illness and in-hospital mortality of COVID-19 patients: A
477 retrospective cohort of 1,792 patients in Kenya. *Biosaf Heal*. 2022;4: 330–338.
478 doi:<https://doi.org/10.1016/j.bsheal.2022.06.002>

- 479 57. Chen U-I, Xu H, Krause TM, Greenberg R, Dong X, Jiang X. Factors Associated With
480 COVID-19 Death in the United States: Cohort Study. *JMIR Public Heal Surveill.* 2022;8:
481 e29343. doi:10.2196/29343
- 482 58. Xu PP, Tian RH, Luo S, Zu ZY, Fan B, Wang XM, et al. Risk factors for adverse clinical
483 outcomes with COVID-19 in China: a multicenter, retrospective, observational study.
484 *Theranostics.* 2020;10: 6372–6383. doi:10.7150/thno.46833
- 485 59. Bhaskaran K, Bacon S, Evans SJ, Bates CJ, Rentsch CT, MacKenna B, et al. Factors
486 associated with deaths due to COVID-19 versus other causes: population-based cohort
487 analysis of UK primary care data and linked national death registrations within the
488 OpenSAFELY platform. *Lancet Reg Heal - Eur.* 2021;6: 100109.
489 doi:10.1016/j.lanepe.2021.100109
- 490 60. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus
491 associated with mortality and severity of COVID-19? A meta-analysis. *Diabetes Metab*
492 *Syndr Clin Res Rev.* 2020;14: 535–545. doi:10.1016/j.dsx.2020.04.044
- 493 61. Burki T. COVID-19 and diabetes in Africa: a lethal combination. *Lancet Diabetes*
494 *Endocrinol.* 2022;10: 23. doi:10.1016/S2213-8587(21)00315-6
- 495 62. Fina Lubaki J-P, Omole OB, Francis JM. Glycaemic control among type 2 diabetes
496 patients in sub-Saharan Africa from 2012 to 2022: a systematic review and meta-
497 analysis. *Diabetol Metab Syndr.* 2022;14: 134. doi:10.1186/s13098-022-00902-0
- 498 63. Birabaharan M, Kaelber DC, Pettus JH, Smith DM. Risk of New-Onset Type 2 Diabetes
499 Mellitus in 600,055 Persons after COVID-19: a cohort study. *Diabetes, Obes Metab.*
500 2022;24: 1176–1179. doi:10.1111/dom.14659
- 501 64. Tazare J, Walker AJ, Tomlinson LA, Hickman G, Rentsch CT, Williamson EJ, et al. Rates
502 of serious clinical outcomes in survivors of hospitalisation with COVID-19 in England: a

- 503 descriptive cohort study within the OpenSAFELY platform. Wellcome Open Res. 2022;7:
504 142. doi:10.12688/wellcomeopenres.17735.1
- 505 65. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study.
506 lancet Diabetes Endocrinol. 2022;10: 311–321. doi:10.1016/S2213-8587(22)00044-4
- 507 66. Madan J, Blonquist T, Rao E, Marwaha A, Mehra J, Bharti R, et al. Effect of COVID-19
508 Pandemic-Induced Dietary and Lifestyle Changes and Their Associations with Perceived
509 Health Status and Self-Reported Body Weight Changes in India: A Cross-Sectional
510 Survey. Nutrients. 2021;13: 3682. doi:10.3390/nu13113682
- 511 67. O’Connell M, Smith K, Stroud R. The dietary impact of the COVID-19 pandemic. J Health
512 Econ. 2022;84: 102641. doi:10.1016/j.jhealeco.2022.102641
- 513 68. Haider N, Osman AY, Gadzekpo A, Akipede GO, Asogun D, Ansumana R, et al. Lockdown
514 measures in response to COVID-19 in nine sub-Saharan African countries. BMJ Glob
515 Heal. 2020;5: e003319. doi:10.1136/bmjgh-2020-003319
- 516 69. Sseguya W, James S, Manfred B, Munyagwa M, Klatman E, Ogle G, et al. Impact of
517 COVID-19 pandemic on young persons with type 1 diabetes in western Uganda.
518 Manuscr Submitt Publ. 2021.
- 519 70. Kebirungi H, Mwenyango H. Impacts of COVID-19 Pandemic Lockdown on the
520 Livelihoods of Male Commercial Boda-Boda Motorists in Uganda. In: Laituri M,
521 Richardson RB, Kim J, editors. The Geographies of COVID-19: Geospatial Stories of a
522 Global Pandemic. Cham: Springer International Publishing; 2022. pp. 195–207.
523 doi:10.1007/978-3-031-11775-6_16
- 524 71. Hrynck TA, Ripoll Lorenzo S, Carter SE. COVID-19 response: mitigating negative
525 impacts on other areas of health. BMJ Glob Heal. 2021;6: e004110. doi:10.1136/bmjgh-
526 2020-004110

- 527 72. Uwizeyimana T, Hashim HT, Kabakambira JD, Mujoyarugamba JC, Dushime J,
528 Ntacyabukura B, et al. Drug supply situation in Rwanda during COVID-19: issues, efforts
529 and challenges. *J Pharm Policy Pract.* 2021;14: 12. doi:10.1186/s40545-021-00301-2
- 530 73. Amu H, Dowou RK, Saah FI, Efunwole JA, Bain LE, Tarkang EE. COVID-19 and Health
531 Systems Functioning in Sub-Saharan Africa Using the “WHO Building Blocks”: The
532 Challenges and Responses. *Front Public Heal.* 2022;10. doi:10.3389/fpubh.2022.856397
- 533 74. Moolla I, Hiilamo H. Health system characteristics and COVID-19 performance in high-
534 income countries. *BMC Health Serv Res.* 2023;23: 244. doi:10.1186/s12913-023-09206-z
- 535 75. Ayanore MA, Amuna N, Aviisah M, Awolu A, Kipo-Sunyezi DD, Mogre V, et al. Towards
536 Resilient Health Systems in Sub-Saharan Africa: A Systematic Review of the English
537 Language Literature on Health Workforce, Surveillance, and Health Governance Issues
538 for Health Systems Strengthening. *Ann Glob Heal.* 2019;85. doi:10.5334/aogh.2514
- 539 76. Tran DN, Kangogo K, Amisi JA, Kamadi J, Karwa R, Kiragu B, et al. Community-based
540 medication delivery program for antihypertensive medications improves adherence and
541 reduces blood pressure. Weinrauch LA, editor. *PLoS One.* 2022;17: e0273655.
542 doi:10.1371/journal.pone.0273655

543

544 **Supporting information**

545 S1 PRISMA-ScR Checklist

546 S2 Search strategy

547 S3 Themes

548




Fig. 1: PRISMA-ScR diagram reporting outcomes of the systematic scoping review process.